Skip to main content

Table 2 The baseline characteristics of the participants by intervention, placebo groups and overall

From: Evaluating the efficacy and safety of GKT137831 in adults with type 1 diabetes and persistently elevated urinary albumin excretion: a statistical analysis plan

Baseline characteristicIntervention (GKT137831) group (n = xxx)Placebo group (n = xxx)Percentage standardised differenceOverall (n = xxx)
ValuesMissing, n (%)ValuesMissing, n (%)ValuesMissing, n (%)
Urine albumin–creatinine ratio (UACR) (log-transformed)       
 Mean (standard deviation (SD))       
Estimated glomerular filtration rate (eGFR) (log-transformed)       
 Mean (SD)       
 Male, n (%)       
 Female, n (%)       
Age (years),       
 Mean (SD)       
 xx, n (%)       
 Other, n (%)       
Clinical variables       
 Systolic blood pressure (mmHg), mean (SD)       
 Diastolic blood pressure (mmHg), mean (SD)       
 Use of angiotensin-converting-enzyme inhibitor (ACEi), n (%)       
 Use of angiotensin II receptor blocker (ARB), n (%)       
 Body mass index (kg/m2), mean (SD)       
 Duration of diabetes mellitus at baseline (years), mean (SD)       
 Glycated haemoglobin (HbA1c %), median (25th–75th percentile)